← boardnext 2026-08
ENSC
Ensysce Biosciencesdistress 8/10 · high distress / dilution risk$0.28-3%today-89% from 52w high
Lead: Postoperative Pain
Revenue
pre-revenue
Liquidity
$1M
Runway
0.1 yrs
Shares 1y
+395%
Price & events
-68.9% over 6M
CatalystRating changeDilutionFinancingdashed = today
-2.8%
1D
-0.3%
1W
+0.4%
1M
-34.9%
3M
-67.9%
6M
-87.6%
1Y
-95.4%
2Y
-100.0%
5Y
-100.0%
All
Overview
- Market Cap
- $4.06M
- Volume
- 26.73K
- 52 Week Range
- $0.25 – $2.57
- Total Shares
- 14.69M
- Float Shares
- 14.68M
- Short %
- 1.19%
- % Held by Insiders
- 0.06%
- % Held by Institutions
- 3.31%
- RVOL
- 0.02x
- Beta
- 0.79
Pipeline stages · 1 programs
PF614 capsule
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-08 Estimated 50% readout ~2026-10-15 | Phase 3 | PF614 capsule | Postoperative Pain, Acute | — | recruiting |
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $16 (+5858% upside) · 1 analysts
- no recent rating changes
Competitors — Postoperative Pain
- CASIFCASI Pharmaceuticals, Inc.$3M · D4
Recent news
- 2026-07-18ENSC News | ENSYSCE BIOSCIENCES INC (NASDAQ:ENSC) - ChartMill
- 2026-07-15Ensysce Biosciences COO Jeffrey Millard resigns effective July 10, 2026 - TradingView
- 2026-07-15COO Jeffrey Millard exits Ensysce Biosciences (Nasdaq: ENSC) July 10 - Stock Titan
- 2026-07-15Ensysce Biosciences, Inc. Announces Resignation of Jeffrey Millard as Chief Operating Officer, Effective July 10, 2026 - marketscreener.com
- 2026-07-14Ensysce receives $5.3M NIDA award for opioid overdose therapy - Investing.com UK
- 2026-07-14Ensysce Biosciences Receives Final $5.3 Million NIDA Funding Installment for PF614-MPAR Development - Yahoo Finance
- 2026-07-14Federal funds back Ensysce opioid technology designed to limit overdose - Stock Titan
- 2026-06-29[EFFECT] Ensysce Biosciences, Inc. SEC Filing - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.